Brief: Gilead Sciences Exercises Option To License Assembly Biosciences’ Helicase-Primase Inhibitor Programs For Recurrent Genital Herpes
22/12/2025 13:20
Dec 22 (Reuters) - Assembly Biosciences Inc ASMB.O: GILEAD SCIENCES EXERCISES OPTION TO LICENSE ASSEMBLY BIOSCIENCES’ HELICASE-PRIMASE INHIBITOR PROGRAMS FOR RECURRENT GENITAL HERPES GILEAD - ASSEMBLY BIO TO RECEIVE $35 MILLION FOR GILEAD'S HSV OPTION Source text: ID:nBw9s5GZKa Further company coverage: ASMB.O ((Reuters.Briefs@thomsonreuters.com;))